Clinical Trials Browser

Terminated × Breast Neoplasms × ixabepilone × Clear all

NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2 Terminated

13 enrolled 8 charts

Breast Neoplasms

NCT03393741 2024-06-25

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Breast Neoplasms

NCT00765765 2023-08-09

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Terminated

6 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase 1 Terminated

31 enrolled 12 charts

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT00546364 2016-03-10

IXTEND

Phase 2 Terminated

62 enrolled 14 charts

Breast Neoplasms

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase 1 Terminated

13 enrolled 13 charts

Breast Neoplasms

NCT00998738 2016-02-04

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

Phase 3 Terminated

1 enrolled 1 chart

Breast Neoplasms, Pain

NCT00079326 2014-06-02

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

39 enrolled 8 charts

Breast Neoplasms

NCT00790894 2011-05-18

HIT

Phase 2 Terminated

Breast Neoplasms